Arthneeti
AE

Advanced Enzyme Technologies Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Advanced Enzyme Technologies Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹300
Market cap₹3.7K Cr
P/E24.0
Updated23 Aug 2026
Read4 min read

What the Q4 FY26 call signalled

2 of 4 strong

RevenueRank 3
MarginRank 3
CapexYes
Order bookYes

Not discussed on this call: fundraise.

The short version

The company expects steady double-digit growth in overall sales/revenue, driven by broad-based growth across human nutrition, animal nutrition, and other segments. The company is confident about sustaining steady growth momentum into the coming years, supported by broader market adoption of enzymes across pharmaceuticals, nutraceuticals, and biotechnology sectors.

From Advanced Enzyme Technologies Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Rank 3
  • The company expects steady double-digit growth in overall sales/revenue, driven by broad-based growth across human nutrition, animal nutrition, and other segments. (Page 13, 14)
  • Moderate growth is anticipated from emerging areas like biocatalysis and new products under trial, with some launches expected this year. (Page 13)
  • U.S. business is under pressure with a challenging market environment, but the company is working on regulatory registrations and increasing market share for future growth. (Pages 20, 8)
  • Indian business showed strong growth, expected to continue, fueled by volume growth and some potential price increases. (Pages 8, 9)
  • The company focuses on innovation and deeper customer engagement for sustainable growth beyond just volume-driven growth. (Pages 11, 12)
  • Growth in probiotics is present but shifting towards solutions rather than individual commodity products. (Page 20)

Profitability & Margins

See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes
  • The company plans an incremental capital expenditure (CapEx) of about INR 50 crores this year.
  • Overall R&D CapEx is expected to be around INR 130 crores, including INR 50 million increase in R&D revenue expenditure.
  • Infrastructure buildup is largely in place, allowing for a 50% capacity increase in fermentation capacity without immediate expansion.
  • A capacity expansion decision will be taken after September; some incremental capacity expansion may occur in a subsidiary.
  • The new R&D facility is expected to be operational in the second half of the year, aiming to triple R&D capacity eventually.
  • The company is also focusing on modern machinery in R&D centers to boost output with fewer people.
  • The strategy includes continuous investments to expand in emerging growth areas like non-meat proteins and biocatalysis.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1Accretion Pharmaceuticals Ltd
Rev 1Mar 2
2OneSource Speci.
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Yes
The transcript from the provided pages does not explicitly mention the current or expected order book or pending orders. However, from the discussion, some relevant insights include: - The company is focusing on steady growth across segments including human nutrition, animal nutrition, and probiotics. - There is an emphasis on expanding the U.S. market despite challenges and changing market dynamics. - Moderate growth is expected in new product areas such as biocatalysis and proprietary solutions using probiotics. - The company maintains a strong R&D pipeline with active product trials underway. - Inventory build-up is a strategic move to manage supply uncertainties, indicating preparation for fulfilling orders. - The company aims for long-term double-digit growth and is focusing on increasing share from existing customers and new markets. No direct numeric data on order book or pending orders is provided in the excerpt.

Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹203 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Advanced Enzyme's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Torrent Pharmaceuticals Ltd (Q4 FY26)

    Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…

  • Kwality Pharma (Q4 FY26)

    FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…

  • RPG Life Sciences Ltd (Q4 FY26)

    Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…

  • Sai Parenteral's (Q4 FY26)

    Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Advanced Enzyme Technologies Ltd Q4 FY26 results?

The company expects steady double-digit growth in overall sales/revenue, driven by broad-based growth across human nutrition, animal nutrition, and other segments. The company is confident about sustaining steady growth momentum into the coming years, supported by broader market adoption of enzymes across pharmaceuticals, nutraceuticals, and biotechnology sectors.

What is Advanced Enzyme Technologies Ltd share price analysis?

Advanced Enzyme Technologies Ltd currently shows a below-average growth signal. The stock trades at a P/E of 24.0 with a market cap of ₹3,726 Cr. Investors should review the full earnings analysis for detailed insights.

Is Advanced Enzyme Technologies Ltd planning capital expenditure?

The company plans an incremental capital expenditure (CapEx) of about INR 50 crores this year.

Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.